Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,846 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 41,600 · Balance 112,846 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:15 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 41,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261768 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,846 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:49 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GiftCommon Stock | 25,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001802653-26-000003 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,246 F1 · kind: Represents a gift to a charitable organization. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 01:10 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,000 | $4.59 | $32,130.00 |
DisclosureSEC source: 0000950170-25-087025 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,082 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.58 to $4.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 21:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 59,225 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083890 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,082 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 5, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 22:45 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,000 | $5.17 | $25,863.00 |
DisclosureSEC source: 0000950170-24-128115 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,857 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.195, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 37,578 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-24-063017 · ownership.xml · derivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,578 Underlying: Common Stock · 37,578 shares Expires 2034-05-16 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| May 17, 2024 Filed May 21, 2024 20:53 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 20,529 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063017 · ownership.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,857 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 17, 2025, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| August 10, 2023 Filed Aug 11, 2023 20:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 6,500 | $6.05 | $39,349.05 |
DisclosureSEC source: 0001209191-23-045447 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,328 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.0952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 33,960 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036285 · doc4.xml · derivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,960 Underlying: Common Stock · 33,960 shares Expires 2033-06-07 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:19 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 17,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036285 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,828 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 8, 2024, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:55 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 24,707 | $0.00 Strike: $9.37 | $0.00 |
DisclosureSEC source: 0001209191-22-038448 · doc4.xml · derivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,707 Underlying: Common Stock · 24,707 shares Expires 2032-06-15 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:55 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 12,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038448 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,521 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 16, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 00:37 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 2,700 | $9.48 | $25,593.03 |
DisclosureSEC source: 0001209191-22-036835 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,515 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.431 to $9.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (right to buy) · Derivative | 13,124 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001209191-21-055685 · doc4.xml · derivative · entry 5 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,876 Underlying: Common Stock · 13,124 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested with respect to 25% of the underlying shares on February 14, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (right to buy) · Derivative | 5,985 | $0.00 Strike: $10.57 | $0.00 |
DisclosureSEC source: 0001209191-21-055685 · doc4.xml · derivative · entry 4 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,985 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 19,109 | $16.74 | $319,976.38 |
DisclosureSEC source: 0001209191-21-055685 · doc4.xml · nonDerivative · entry 3 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,215 F1 · kind: A portion of the shares was sold to satisfy the exercise price of the stock options. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.53 to $16.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 13,124 | $12.70 | $166,674.80 |
DisclosureSEC source: 0001209191-21-055685 · doc4.xml · nonDerivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 20:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 5,985 | $10.57 | $63,261.45 |
DisclosureSEC source: 0001209191-21-055685 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionStock Option (right to buy) · Derivative | 4,015 | $0.00 Strike: $10.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041496 · doc4.xml · derivative · entry 3 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,985 Underlying: Common Stock · 4,015 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested and became exercisable with respect to 100% of the option shares on June 11, 2021. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 5,000 | $19.42 | $97,122.00 |
DisclosureSEC source: 0001209191-21-041496 · doc4.xml · nonDerivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,215 F1 · kind: A portion of the shares was sold to satisfy the exercise price of the stock option and the tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 21:01 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 4,015 | $10.57 | $42,438.55 |
DisclosureSEC source: 0001209191-21-041496 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.21 | $0.00 |
DisclosureSEC source: 0001209191-21-040240 · doc4.xml · derivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:36 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040240 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,200 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 10, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $10.57 | $0.00 |
DisclosureSEC source: 0001209191-20-036783 · doc4.xml · derivative · entry 2 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F2 · derivative.exercise_date: This option vests and becomes exercisable with respect to 100% of the option shares on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 23:11 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036783 · doc4.xml · nonDerivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 11, 2021, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:20 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $12.70 | $0.00 |
DisclosureSEC source: 0001209191-20-010516 · doc4.xml · derivative · entry 1 Mitchell Stephen Ray · CIK 0001802653 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common · 35,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares when the Reporting Person completes 12 months of continuous service following the date of grant, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.